| Systematic exploration of essential yeast gene function with temperature-sensitive mutants Z Li, FJ Vizeacoumar, S Bahr, J Li, J Warringer, FS Vizeacoumar, R Min, ... Nature biotechnology 29 (4), 361-367, 2011 | 436 | 2011 |
| Essential gene profiles in breast, pancreatic, and ovarian cancer cells R Marcotte, KR Brown, F Suarez, A Sayad, K Karamboulas, ... Cancer discovery 2 (2), 172-189, 2012 | 375 | 2012 |
| Global gene deletion analysis exploring yeast filamentous growth O Ryan, RS Shapiro, CF Kurat, D Mayhew, A Baryshnikova, B Chin, ... Science 337 (6100), 1353-1356, 2012 | 243 | 2012 |
| Multilayered control of alternative splicing regulatory networks by transcription factors H Han, U Braunschweig, T Gonatopoulos-Pournatzis, RJ Weatheritt, ... Molecular cell 65 (3), 539-553. e7, 2017 | 160 | 2017 |
| Integrating high-throughput genetic interaction mapping and high-content screening to explore yeast spindle morphogenesis FJ Vizeacoumar, N van Dyk, F S. Vizeacoumar, V Cheung, J Li, ... Journal of cell biology 188 (1), 69-81, 2010 | 115 | 2010 |
| A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities FJ Vizeacoumar, R Arnold, FS Vizeacoumar, M Chandrashekhar, ... Molecular systems biology 9 (1), 696, 2013 | 108 | 2013 |
| Molecular characterization of breast cancer cell lines through multiple omic approaches SE Smith, P Mellor, AK Ward, S Kendall, M McDonald, FS Vizeacoumar, ... Breast Cancer Research 19, 1-12, 2017 | 97 | 2017 |
| RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs TJW Robinson, JC Liu, F Vizeacoumar, T Sun, N Maclean, SE Egan, ... PloS one 8 (11), e78641, 2013 | 93 | 2013 |
| Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming CL Hirsch, ZC Akdemir, L Wang, G Jayakumaran, D Trcka, A Weiss, ... Genes & development 29 (8), 803-816, 2015 | 84 | 2015 |
| High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors T Robinson, M Pai, J Liu, F Vizeacoumar, T Sun, S Egan, A Datti, J Huang, ... Cell Cycle 12 (18), 3013-3024, 2013 | 84 | 2013 |
| Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors SC Chafe, FS Vizeacoumar, G Venkateswaran, O Nemirovsky, S Awrey, ... Science advances 7 (35), eabj0364, 2021 | 77 | 2021 |
| Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2012; 2 (2): 172–89. doi: 10.1158/2159-8290 R Marcotte, KR Brown, F Suarez, A Sayad, K Karamboulas, ... CD-11-0224.[PubMed][Cross Ref], 2012 | 64 | 2012 |
| Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers AK Ward, P Mellor, SE Smith, S Kendall, NA Just, FS Vizeacoumar, ... Breast Cancer Research 18, 1-21, 2016 | 59 | 2016 |
| PicOS: A Tiny Operating System for Extremely Small Embedded Platforms. E Akhmetshina, P Gburzynski, FS Vizeacoumar Embedded Systems and Applications, 116-122, 2003 | 51 | 2003 |
| Protein tyrosine kinases: their roles and their targeting in leukemia K K. Bhanumathy, A Balagopal, FS Vizeacoumar, FJ Vizeacoumar, ... Cancers 13 (2), 184, 2021 | 43 | 2021 |
| An integrated computational and experimental study uncovers FUT 9 as a metabolic driver of colorectal cancer N Auslander, CE Cunningham, BM Toosi, EJ McEwen, K Yizhak, ... Molecular Systems Biology 13 (12), 956, 2017 | 43 | 2017 |
| EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours BM Toosi, A El Zawily, L Truitt, M Shannon, O Allonby, M Babu, ... Oncogene 37 (30), 4073-4093, 2018 | 38 | 2018 |
| Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer F Ghasemi, M Black, F Vizeacoumar, N Pinto, KM Ruicci, CCSH Le, ... Oncotarget 8 (42), 71512, 2017 | 34 | 2017 |
| A road map to personalizing targeted cancer therapies using synthetic lethality S Parameswaran, D Kundapur, FS Vizeacoumar, A Freywald, ... Trends in Cancer 5 (1), 11-29, 2019 | 33 | 2019 |
| Therapeutic relevance of the protein phosphatase 2A in cancer CE Cunningham, S Li, FS Vizeacoumar, KK Bhanumathy, JS Lee, ... Oncotarget 7 (38), 61544, 2016 | 31 | 2016 |
Franco VizeacoumarAssociate Professor, University of Saskatchewan, Saskatchewan Cancer Agency在 usask.ca 的电子邮件经过验证
